Serum retinol‐binding protein 4 is not increased in obesity or obesity‐associated type 2 diabetes mellitus, but is reduced after relevant reductions in body fat following gastric bypass

Objective  Controversy exists regarding the elevation of serum retinol‐binding protein 4 (RBP4) in human obesity and type 2 diabetes mellitus (T2DM). In the present study, we have compared serum RBP4 in lean and obese patients with or without T2DM, and analysed the effect of weight loss on serum RBP4.

[1]  E. Mannarino,et al.  The endocrine function of adipose tissue: an update , 2006, Clinical endocrinology.

[2]  Nimesh Mody,et al.  Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes , 2005, Nature.

[3]  G. Frühbeck,et al.  Evidence for the involvement of resistin in inflammation and cardiovascular disease. , 2005, Current diabetes reviews.

[4]  F. Rubiano,et al.  Air displacement plethysmography: validation in overweight and obese subjects. , 2005, Obesity research.

[5]  K. Park,et al.  Plasma Retinol-Binding Protein-4 Concentrations Are Elevated in Human Subjects With Impaired Glucose Tolerance and Type 2 Diabetes , 2007, Diabetes Care.

[6]  Arya M. Sharma,et al.  Retinol-Binding Protein 4 in Human Obesity , 2006, Diabetes.

[7]  D. Goodman,et al.  Localization of retinol-binding protein messenger RNA in the rat kidney and in perinephric fat tissue. , 1989, Journal of lipid research.

[8]  A. Pfeiffer,et al.  Microalbuminuria is a major determinant of elevated plasma retinol-binding protein 4 in type 2 diabetic patients. , 2007, Kidney international.

[9]  P. Arner.  Resistin: yet another adipokine tells us that men are not mice , 2005, Diabetologia.

[10]  M. Blüher,et al.  Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects , 2007, Diabetologia.

[11]  M. Fasshauer,et al.  Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. , 2007, Cell metabolism.

[12]  J. Dickerson,et al.  Retinol, α-tocopherol and carotenoids in diabetes , 1999, European Journal of Clinical Nutrition.

[13]  G. Frühbeck,et al.  The obestatin receptor (GPR39) is expressed in human adipose tissue and is down‐regulated in obesity‐associated type 2 diabetes mellitus , 2007, Clinical endocrinology.

[14]  R. Kimmig,et al.  Retinol-binding protein 4 levels are elevated in polycystic ovary syndrome women with obesity and impaired glucose metabolism. , 2007, European journal of endocrinology.

[15]  F. Capel,et al.  Plasma levels and adipose tissue messenger ribonucleic acid expression of retinol-binding protein 4 are reduced during calorie restriction in obese subjects but are not related to diet-induced changes in insulin sensitivity. , 2007, The Journal of clinical endocrinology and metabolism.

[16]  G. Frühbeck,et al.  The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. , 2001, American journal of physiology. Endocrinology and metabolism.

[17]  V. Funanage,et al.  Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. , 2007, The Journal of clinical endocrinology and metabolism.

[18]  Bounleut Phanavanh,et al.  Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. , 2007, The Journal of clinical endocrinology and metabolism.

[19]  E. E. Wein,et al.  Vitamin A (retinol) status of first nation adults with non-insulin-dependent diabetes mellitus. , 1997, Journal of the American College of Nutrition.

[20]  E. Kraegen,et al.  Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. , 2007, Clinical chemistry.

[21]  P. Lepper,et al.  Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease , 2007, Diabetologia.

[22]  J. Shaw,et al.  Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.

[23]  S. Kahn,et al.  Mechanisms linking obesity to insulin resistance and type 2 diabetes , 2006, Nature.

[24]  F. R. Smith,et al.  The effects of diseases of the liver, thyroid, and kidneys on the transport of vitamin A in human plasma. , 1971, The Journal of clinical investigation.

[25]  J. Fernández-Real,et al.  Circulating Retinol-Binding Protein-4, Insulin Sensitivity, Insulin Secretion, and Insulin Disposition Index in Obese and Nonobese Subjects , 2007, Diabetes Care.

[26]  I. Stefanidis,et al.  Serum Levels of Adipokine Retinol-Binding Protein-4 in Relation to Renal Function , 2008, Diabetes Care.

[27]  B. Pedersen,et al.  Retinol-binding protein 4 and insulin resistance. , 2006, The New England journal of medicine.

[28]  Michael Stumvoll,et al.  Type 2 diabetes: principles of pathogenesis and therapy , 2005, The Lancet.

[29]  Vahram Ghushchyan,et al.  Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. , 2005, Diabetes care.

[30]  Jaewon Oh.  Retinol-binding protein 4 and insulin resistance. , 2006, The New England journal of medicine.

[31]  M. Wolzt,et al.  Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. , 2007, The Journal of clinical endocrinology and metabolism.

[32]  P. Arner.  Insulin resistance in type 2 diabetes -- role of the adipokines. , 2005, Current molecular medicine.

[33]  Y. Aso,et al.  Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. , 2007, The Journal of clinical endocrinology and metabolism.

[34]  Mark M. Melendez,et al.  Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes. , 2007, The Journal of clinical endocrinology and metabolism.

[35]  U. Smith,et al.  Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. , 2006, The New England journal of medicine.

[36]  S. Genuth.  Lowering the criterion for impaired fasting glucose is in order. , 2003, Diabetes care.

[37]  G. Frühbeck,et al.  Plasma osteopontin levels and expression in adipose tissue are increased in obesity. , 2007, The Journal of clinical endocrinology and metabolism.